NASDAQ:CDTX - Cidara Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.38 -0.04 (-1.65 %) (As of 04/18/2019 04:00 PM ET)Previous Close$2.42Today's Range$2.36 - $2.4352-Week Range$1.94 - $6.35Volume78,267 shsAverage Volume89,400 shsMarket Capitalization$66.20 millionP/E RatioN/ADividend YieldN/ABeta2.24 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California. Receive CDTX News and Ratings via Email Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDTX Previous Symbol CUSIPN/A CIK1610618 Webwww.cidara.com Phone858-752-6170Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book1.12Profitability EPS (Most Recent Fiscal Year)($2.32) Net Income$-59,020,000.00 Net MarginsN/A Return on Equity-90.06% Return on Assets-67.61%Miscellaneous Employees68 Outstanding Shares27,816,000Market Cap$66.20 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions What is Cidara Therapeutics' stock symbol? Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX." How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics Inc (NASDAQ:CDTX) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.11. View Cidara Therapeutics' Earnings History. When is Cidara Therapeutics' next earnings date? Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Cidara Therapeutics. What price target have analysts set for CDTX? 5 equities research analysts have issued 1 year price objectives for Cidara Therapeutics' shares. Their forecasts range from $7.00 to $15.00. On average, they anticipate Cidara Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 362.2% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics. What is the consensus analysts' recommendation for Cidara Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics. What are Wall Street analysts saying about Cidara Therapeutics stock? Here are some recent quotes from research analysts about Cidara Therapeutics stock: 1. Cantor Fitzgerald analysts commented, "CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15." (4/15/2019) 2. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (2/11/2019) Has Cidara Therapeutics been receiving favorable news coverage? Media coverage about CDTX stock has been trending positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cidara Therapeutics earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. Who are some of Cidara Therapeutics' key competitors? Some companies that are related to Cidara Therapeutics include Eiger Biopharmaceuticals (EIGR), Novavax (NVAX), ADMA Biologics (ADMA), Jounce Therapeutics (JNCE), Gamida Cell (GMDA), La Jolla Pharmaceutical (LJPC), Neon Therapeutics (NTGN), Compugen (CGEN), AVITA MED LTD/S (AVMXY), Erytech Pharma (ERYP), Allena Pharmaceuticals (ALNA), Organovo (ONVO), Oncobiologics (ONS), Surface Oncology (SURF) and Brainstorm Cell Therapeutics (BCLI). What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Exelixis (EXEL), Nektar Therapeutics (NKTR), T2 Biosystems (TTOO) and Tetraphase Pharmaceuticals (TTPH). Who are Cidara Therapeutics' key executives? Cidara Therapeutics' management team includes the folowing people: Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)Dr. Taylor Sandison, Chief Medical Officer (Age 47)Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)Mr. James E. Levine, Chief Financial Officer (Age 48)Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50) When did Cidara Therapeutics IPO? (CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. How do I buy shares of Cidara Therapeutics? Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cidara Therapeutics' stock price today? One share of CDTX stock can currently be purchased for approximately $2.38. How big of a company is Cidara Therapeutics? Cidara Therapeutics has a market capitalization of $66.20 million. The biotechnology company earns $-59,020,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe. What is Cidara Therapeutics' official website? The official website for Cidara Therapeutics is http://www.cidara.com. How can I contact Cidara Therapeutics? Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected] MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 230 (Vote Underperform)Total Votes: 538MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/18/2019 by MarketBeat.com StaffFeatured Article: What are convertible shares?